Increased interest has focused on associations between dietary fatty acids and cardiovascular disease (CVD). Current findings delineating effects of consuming saturated fatty acids (SFA) from dairy on CVD risk remain controversial. The objective of this thesis was to investigate the effects of consuming two types of dairy fat, namely those from cheese and butter on, human plasma and RBC fatty acid profiles, compared with monounsaturated fatty acids (MUFA), polyunsaturated fatty acids (PUFA) and carbohydrate (CHO). A secondary objective was to investigate the association between consuming these dietary fatty acids and endogenous de novo fatty acid synthesis. A randomized, full-feeding, crossover, single-blinded clinical trial was conducted at the Institute of Nutrition and Functional Foods (INAF), Laval University and Richardson Centre for Functional Foods and Nutraceuticals (RCFFN), the University of Manitoba. A total of 92 women and men with abdominal obesity and relative low high density lipoprotein cholesterol (HDL-C) levels were randomized into a series of 5 treatments. The duration of each treatment was 4 weeks and separated by at least 4 weeks washout period. For plasma fatty acid profile, total plasma SFA after cheese treatment was found to be higher (P<0.05) than after MUFA, PUFA and CHO treatments, whereas total plasma SFA after butter treatment was only found to be higher (P<0.05) than after MUFA and PUFA treatments. Total plasma MUFA after MUFA treatment was higher (P<0.05) than after all other treatments, and total plasma PUFA after PUFA treatment was higher (P<0.05) than after all other treatments. Unlike plasma fatty acid profile, RBC total SFA after two dairy treatments were not higher than after CHO and PUFA treatments. Consistent with the plasma fatty acid profile, RBC total MUFA after MUFA treatment were found to be higher (P<0.05) than after all other treatments. Similarly, RBC total PUFA after PUFA treatment were higher (P<0.05) than after all other treatments. We did not detect any differences in de novo palmitic acid synthesis across all treatments in the present study. However, we did see a positive correlation between de novo palmitic acid synthesis and body fat mass. In summary, present results suggest that consuming dairy fats, from cheese or butter, can significantly modulate plasma fatty acids in a manner that increases plasma total SFA, including myristic acid (C14:0), pentadecanoic acid (C15:0), palmitic acid (C16:0) and heptadecanoic acid (C17:0). However, the effect of consuming dairy fats on RBC fatty acid profile is relatively minor. Additionally, the de novo fatty acid synthesis data suggests that the quality of dietary fatty acids does not associate with human endogenous fatty acid synthesis; unlike body fat mass. / May 2017

No description available.

Abstract Though not a life threatening condition, involuntary loss of urine is a miserable situation. It has a multidimensional effect on the afflicted individuals, both men and women – and for the society. The purpose of this study was to evaluate two modern, minimally invasive surgical techniques for the treatment of female stress urinary incontinence (SUI). The techniques evaluated were laparoscopic colposuspension with mesh and staples (LCM) and the tension-free vaginal tape procedure (TVT). The study consisted of four parts. The first part (Study I) was an observational retrospective follow-up study. Data on the first forty patients operated on with LCM at Oulu University Hospital were collected. Patients had SUI or mixed urinary incontinence (MUI) with predominantly stress incontinence. The Studies II–IV were parts of a randomized, multicenter clinical trial, where LCM was compared with TVT. According to the predefined inclusion criteria 128 SUI women were randomly allocated into two treatment groups: 70 patients received TVT treatment as allocated and 51 LCM. There were seven drop-outs after randomization. After one year of follow-up the cure and improvement rate of the patients operated with LCM were ~ 90%. Also a significant improvement was found in Urinary Incontinence Severity Scores (UISS). At base line the score was 12.1 and after one year follow-up 2.7 (p &lt; 0.001). The bladder perforation rate was 15%. In Study II immediate cure rates and complications of LCM and TVT were studied. After six weeks of follow-up there was no difference in cure rates (~ 90%) between the procedures. There was no difference in complication rates. A significant difference was found in the use of anti-inflammatory / opioid drugs in the immediate post-operative period to relief the pain in favour for TVT. Hospital care was also significantly shorter after TVT than LCM. After one year of follow-up (Study III) TVT was found to give better result both objectively and subjectively. Negative stress test result was recorded in 85.7% in the TVT group and 56.9% in the LCM group. A significant difference was also found, when Visual Analoque Scale (VAS), King's College Health Questionnaire (KHQ) and UISS were used as outcome measures, in the favour of TVT. When 48-hour pad test was used as outcome measure there was no statistically significant difference between the groups. The cost-effectiveness (Study IV) of TVT was found to be better than that of LCM after one year of follow-up. In conclusion, the results of this study suggest, that TVT procedure is on the whole a cost-effective alternative for LCM in the treatment of female SUI.

No description available.

O curso longitudinal do transtorno bipolar é altamente variável, mas um subconjunto de pacientes parece apresentar uma evolução progressiva associada a alterações cerebrais e comprometimento funcional. Em nosso primeiro artigo, discutimos a teoria da neuroprogressão no transtorno bipolar. Este conceito considera a resposta ao estresse que ocorre nos episódios de humor e déficits no funcionamento e cognição, bem como alterações neuroanatômicas nos estágios tardios da doença. Discutimos também refratariedade ao tratamento que pode ocorrer em alguns casos de transtorno bipolar. Foi executada uma busca na base de dados PubMed para artigos publicados em qualquer idioma até 04 de junho de 2016. Foram encontrados 315 resumos e 87 estudos foram incluídos em nossa revisão. Somos da opinião de que o uso de estratégias farmacológicas específicas e remediação funcional pode ser potencialmente útil em pacientes bipolares em estágios tardios. Novas abordagens analíticas que utilizam dados multimodais têm o potencial para ajudar na identificação de assinaturas de subgrupos de pacientes que irão desenvolver um curso neuroprogressivo. Com base em nossa hipótese de neuroprogressão, decidimos realizar um ensaio clínico randomizado com o antidepressivo tianeptina como tratamento adjuvante para o transtorno bipolar, a fim de melhorar o comprometimento funcional, desfechos clínicos e aumentar os níveis do Brain-Derived Neurothrofic Factor (BDNF). Tianeptina é um fármaco seguro, que atua sobre o sistema glutamatérgico e tem um efeito antidepressivo. Esse estudo teve como objetivo avaliar a eficácia e tolerabilidade da tianeptina como tratamento adjuvante para a depressão bipolar. Foi realizado um ensaio clínico duplo-cego randomizado de manutenção controlado por placebo com tianeptina 37,5 mg/dia. Os participantes (n = 161) tinham uma pontuação na Montgomery Asberg Depression Rating ≥12 no início do ensaio. Após oito semanas de tratamento com tianeptina na fase aberta, aqueles que responderam a tianeptina foram randomizados para o placebo ou tianeptina adjuvante. Os participantes foram recrutados na rede pública de saúde. Tempo para qualquer intervenção foi o desfecho primário do estudo. Mudanças nos sintomas de humor, funcionamento, ritmos biológicos, qualidade de vida, taxas de virada maníaca e níveis séricos de BDNF foram considerados como desfechos secundários. Houve uma diminuição importante nos sintomas depressivos, assim como melhoras no funcionamento, qualidade de vida e pontuações no ritmo biológico durante a fase aberta de tratamento com tianeptina por oito semanas. Durante as 24 semanas do ensaio duplo-cego randomizado e controlado por placebo, não houve diferença em relação ao desfecho primário: tempo para qualquer intervenção. Além disso, não houve diferenças significativas entre os grupos em relação aos sintomas de humor, funcionamento e níveis de BDNF. Tianeptina foi bem tolerada e não foi associada a virada maníaca em comparação com o placebo. Estes achados sugerem que tianeptina é um medicamento seguro e pode ser eficaz no tratamento da depressão bipolar aguda. No entanto, tianeptina não mostrou efeitos benéficos na fase de manutenção. Este é o primeiro ensaio clínico duplo-cego randomizado de manutenção e de longo prazo com antidepressivo no transtorno bipolar. / The longitudinal course of bipolar disorder is highly variable, and a subset of patients seems to present a progressive course associated with brain changes and functional impairment. In our first article, we discussed the theory of neuroprogression in bipolar disorder. This concept considers the systemic stress response that occurs within mood episodes and late-stage deficits in functioning and cognition as well as neuroanatomic changes. We also discuss treatment refractoriness that may take place in some cases of bipolar disorder. We searched PubMed for articles published in any language up to June 4th, 2016. We found 315 abstracts and included 87 studies in our review. We are of the opinion that the use of specific pharmacological strategies and functional remediation may be potentially useful in bipolar patients at late-stages. New analytic approaches using multimodal data hold the potential to help in identifying signatures of subgroups of patients who will develop a neuroprogressive course. Based on our hypothesis of neuroprogression, we decided to perform a randomized clinical trial with tianeptine as adjunctive treatment for bipolar disorder in order to improve functional impairment and increase serum Brain-Derived Neurothrophic Factor BDNF levels. Tianeptine is a safe medication that acts on the glutamatergic system and has an antidepressant effect. The present study aimed at assessing the efficacy and tolerability of tianeptine as an adjunctive treatment for bipolar depression. We performed an enriched maintenance multi-center double-blind randomized controlled trial of tianeptine 37•5mg/day. Participants (n = 161) had a Montgomery Asberg Depression Rating Score ≥12 at trial entry. After eight weeks of open-label tianeptine treatment, those who responded to tianeptine were randomized to adjunctive tianeptine or placebo in addition to usual treatment. Participants were recruited from public health services and through advertisement. Time to any intervention was the primary endpoint of the study. Changes in mood symptoms, functioning, biological rhythms, quality of life, rates of mania switch and serum BDNF assessments were considered as secondary outcomes. There was a robust decrease in depressive symptoms along with improvements in functioning, quality of life and biological rhythms scores during the eight-week open-label tianeptine treatment phase. During the subsequent 24-week double-blind controlled phase, there was no difference regarding the primary outcome: time to intervention. In addition, there were no significant differences between groups in mood symptoms, functioning and BDNF levels. Tianeptine was well tolerated and not associated with mania switch as compared to placebo. These findings suggest that tianeptine is a safe medication and may be effective in the treatment of acute bipolar depression. However, tianeptine did not show beneficial effects in the maintenance phase. This is the first long-term randomized, double-blind maintenance trial of antidepressant augmentation in bipolar disorder.

Objetivo: Avaliar o impacto do tratamento periodontal na concentração sérica de proteína C-reativa (PCR), perfil lipídico e hemoglobina glicada em pacientes cardiopatas participantes de um ensaio clínico randomizado com análise de 12 meses de acompanhamento. Métodos: Trata-se de um ensaio clínico randomizado em hospital terciário com pacientes com doença arterial coronariana (DAC) estável e periodontite crônica grave. Foram realizados exames periodontais (seis sítios por dente em toda a boca) para registro de profundidade de sondagem (PS) e perda de inserção (PI), além de índice de placa visível (IPV) e índice de sangramento gengival (ISG). O grupo teste recebeu tratamento periodontal intensivo, sendo inicialmente realizada uma sessão de raspagem, alisamento e polimento supragengival (RAP) com orientação personalizada de higiene bucal. Em seguida, foram realizadas até quatro sessões de raspagem e alisamento radicular subgengival (RASUB) por quadrante, sob anestesia local. O grupo controle recebeu uma única sessão de RAP e orientação de higiene bucal. Foram coletadas amostras para mensuração dos níveis sistêmicos de PCR de alta sensibilidade, perfil lipídico e hemoglobina glicada. Resultados: 60 pacientes foram analisados após 12 meses, 28 no grupo teste e 32 no grupo controle, com idade média de 59 e 61 anos, respectivamente. Não foram observadas diferenças significativas ao longo do tempo, e entre os grupos nos dois tempos experimentais em relação a PCR. Assim como não foram encontradas diferenças significativas entre perfil lipídico e hemoglobina glicada. Conclusão: O tratamento periodontal não adicionou benefício sobre os níveis de PCR, hemoglobina glicada e perfil lipídico em indivíduos cardíacos crônicos tratados em uma unidade terciária. No entanto, foi observada uma tendência de benefício em pacientes cardíacos com níveis basais controlados de PCR. / Objective: To evaluate the impact of periodontal therapy on serum concentration of CRP, lipid profile and glycated hemoglobin in patients with heart disease participating in a randomized clinical trial with 12 months of follow-up. Methods: A randomized clinical trial in a tertiary hospital with patients with stable coronary artery disease (CAD) and severe chronic periodontitis. Whole mouth periodontal examination (six sites per tooth) was performed and comprised probing depth (PD) and attachment loss, in addition to visible plaque (VPI) and gingival bleeding index (GBI) The test group received intensive periodontal treatment. Initially, supragingival scaling with oral hygiene instruction were performed. In sequence, up to four sessions of subgingival scaling root planing per quadrant, under local anesthesia were performed. The control group had supragingival scaling and oral hygiene instruction. Blood samples were collected to assess the serum levels of high sensitivity CRP, lipid profile and glycated hemoglobin. Results: A total of 60 patients were analyzed after twelve moths, 28 (test group) and 32 (control group), with a mean age of 59 and 61 years. No statistically significant differences were observed along the study between groups in CRP. Also, no statistically significant diferences were detected in glycated hemoblobin and lipid profile. Conclusion: Periodontal treatment did not add benefit on CRP and glycated hemoglobina levels as well as in lipid profile in chronic cardiac individuals treated in a tertiary unit. However, a positive trend was observed in cardiac patients with controlled RCP basal levels.

Introdução: As práticas clínicas baseadas em evidências utilizam resultados de estudos bem desenhados e bem conduzidos que, compilados em revisões sistemáticas, auxiliam os profissionais da saúde e orientam-os de modo sintético e atualizado no manejo dos tratamentos. Em um estudo bem conduzido, os dados coletados apresentarão boa qualidade se obtidos a partir de protocolos bem definidos que incluem as orientações para o acompanhamento dos pacientes e ações padronizadas pelos profissionais envolvidos. O monitoramento do estudo permite acompanhar e controlar a execução das ações definidas no protocolo de tal forma que os resultados finais não apresentem vieses de seleção, de desempenho (performance), de detecção, de atrito (attrition) ou de relato. Entre os instrumentos que avaliam a qualidade do relato de ensaios clínicos, nenhum deles destaca a avaliação de ações de monitoramento que, constitui, segundo nosso ponto de vista, um elemento importante para assegurar a qualidade dos dados. Objetivo: Apresentar uma reflexão sobre vieses em ensaios clínicos aleatorizados e sobre o papel do monitoramento do estudo no controle e prevenção destes. Métodos: Estudo metodológico que se propôs a avaliar a qualidade de ensaios clínicos aleatorizados incluídos em uma revisão sistemática escolhida ad hoc que tratou do uso de estatinas na prevenção primária de doença cardiovascular. Análise de vieses dos estudos originais incluídos na revisão sistemática utilizando a ferramenta para avaliação de risco de viés em ensaios clínicos aleatorizados descrita no Cochrane Handbook for Systematic Reviews of Interventions (Manual Cochrane para Revisões Sistemáticas de Intervenção), versão 5.1.0. Foram identificadas e descritas em detalhes as ações do monitoramento que poderiam colaborar na minimização ou possível eliminação dos vieses. Foi realizada uma busca nos artigos originais para verificar se existia a descrição das ações relacionadas ao monitoramento. Resultados: Considerando o critério para possibilidade de ocorrência de cada um dos sete tipos de viés, os estudos BONE, CARDS, METEOR e MRC/BHF apresentaram a maior porcentagem (85,7 por cento ) de baixo risco de ocorrência de vieses, indicando possivelmente boa qualidade metodológica. Em contrapartida, em quatro estudos esta porcentagem foi menor que 50 por cento (estudos ASPEN, CERDIA, HYRIM e KAPS), indicando menor qualidade metodológica. Todos os estudos foram classificados como risco incerto para outras fontes de vieses por apresentarem patrocínio por indústria farmacêutica representando, sob nossa avaliação, conflito de interesse. Observou-se que o estudo AFCAPS/TexCAPS indicou que uma empresa que organiza pesquisas foi contratada pelo patrocinador para manejo administrativo e clínico e também dos dados. Porém, não foram descritos maiores detalhes sobre o monitoramento. Neste estudo, observou-se risco incerto para a geração de sequência aleatória, ocultação da alocação e outros vieses. Os demais potenciais vieses foram classificados como baixo risco. Conclusões: No presente trabalho, verificou-se que mesmo um ensaio clínico bem desenhado, relatado e avaliado como baixo risco para a ocorrência de vieses também está sujeito a ocorrência destes durante a sua condução. Vê-se como necessária a inclusão de um item específico sobre viés de conflito de interesse nos instrumentos de avaliação de qualidade metodológica de estudos. Reforça-se o papel do monitoramento para evitar ou minimizar erros sistemáticos, garantindo que o estudo seja realizado conforme o que foi inicialmente proposto. / Background: The clinical practices based on evidences use results obtained from well designed and conducted studies that compiled in systematic reviews assist and guide health professionals to manage patient treatments. In a well conducted study, data collected will have good quality if obtained from protocols that include guidance for patients follow-up and standardized procedures for personnel involved in the study. The study monitoring allows follow-up and control regarding the execution of tasks required by protocol in order to avoid selection bias, performance bias, detection bias, attrition bias or report bias in study results. The available tools to evaluate the quality of reporting of randomized clinical trials do not describe the monitoring actions that we believe are very important for data quality assurance. Objective: To reflect about bias occurrence in randomized clinical trials and the role of study monitoring in its control and prevention. Methods: Methodological study that evaluated the quality of randomized clinical trials included in a systematic review chosen ad hoc regarding the statin use for the primary prevention of cardiovascular disease. Analysis of the original studies using the Cochrane Collaboration´s tool for assessing risk of bias in randomized clinical trials described in Cochrane Handbook for Systematic Reviews of Interventions, version 5.1.0. The monitoring actions that could avoid or minimize bias occurrence were identified and described in details. A search for actions related to monitoring was also performed in the original articles. Results: Considering the criteria for the possibility of occurence of each of the seven bias types, the studies BONE, CARDS, METEOR and MRC/BHF presented a higher percentage (85.7 per cent ) of low risk for bias, possibly indicating a good methodologic quality. However, this percentage was less than 50 per cent in four studies (ASPEN, CERDIA, HYRIM e KAPS), indicating a poor methodologic quality. All studies were classified as unclear risk for other bias considering that they were sponsored by pharmaceutical industries representing, according to our evaluation, conflict of interest. It was observed that AFCAPS/TexCAPS study indicated that a company responsible for research organization was contracted by the sponsor for data, administrative and clinical management. However, further information about monitoring was not described. In this particular study, random sequence generation, allocation concealment and other bias were classified as unclear risk. The remaining potential biases were classified as low risk. Conclusion: At the present work, it was verified that even clinical trials that are well designed, reported and with low risk for bias might have problems during the study conduction. We understand as necessary the inclusion of a specific item about the bias of conflict of interest in the tools for evaluation of methodology of studies.We emphasize the role of monitoring to avoid or minimize systematic bias, ensuring that the study is performed according to what was initially proposed.

The adverse effects of maternal smoking on infant mortality and morbidity has been well documented in the literature. Maternal tobacco use is causally associated with fetal growth restriction and correlates negatively with folate intake and metabolism. Studies have examined the association between smoking and folate levels during pregnancy, but very few have assessed this relationship using objective and accurate measures of both variables. Furthermore, despite evidence of a causal association between smoking in pregnancy and intrauterine growth restriction, and a plausible relationship between tobacco use and low maternal folate which is required for optimal fetal growth, no experimental study has investigated the potential benefit of folic acid in mitigating the adverse effects of maternal smoking on fetal outcomes. The objectives of this study were to investigate the relationship between maternal smoking and folate levels and examine the efficacy of higher-strength folic acid supplementation, in combination with enrollment in a smoking cessation program, in promoting fetal body and brain growth. Our hypothesis was that women who smoke during pregnancy have lower peri-conceptional folic acid reserves than non-smoker pregnant women and that folic acid reserves will decrease with increasing cotinine level. Additionally, smoker pregnant women on higher-strength folic acid (4mg daily) in combination with smoking cessation programs will experience faster fetal brain growth and have infants with larger body size at birth compared to smokers on the standard dose of folic acid (0.8mg daily). Participants were pregnant women (smokers and non-smokers) who received antenatal care between 2010-2014 at the Genesis Clinic of Tampa, a community health center affiliated with the Department of Obstetrics and Gynecology of the University of South Florida (USF). They were aged 18-44 years and had a gestational age of less than 21 weeks at study enrollment. To determine the peri-conceptional folic acid reserves in smoking versus nonsmoking women during pregnancy and associated sociodemographic factors, baseline (crosssectional) data from a double-blinded randomized controlled trial were analyzed using Tobit regression models (n=496). Smoking information was assessed using salivary cotinine, a sensitive and specific tobacco use biomarker. Folate reserve was measured using red blood cell folate. To investigate the efficacy of higher-strength folic acid on fetal body and brain size, baseline and follow-up data from pregnant smokers enrolled in the randomized controlled trial were utilized (n=345). All primary analyses of the clinical trial data were conducted on a modified intention-to-treat basis and included participants who completed the trial with an observed endpoint, irrespective of compliance to protocol. Multilevel modeling, linear regression, and log-binomial regression analyses were conducted. A significant inverse association between salivary cotinine level and periconceptional red blood cell folate concentration was found among pregnant women in the early to midpregnancy period. Smokers on high-dose folate during pregnancy had infants with a 140.38g higher birth weight than infants of their counterparts on standard dose folate (P =0.047). Mothers who received higher strength folate had a 31.0% lower risk of having babies with SGA compared to their mothers on the standard-dose (adjusted relative risk-ARR=0.69, 95% CI: 0.46–1.03; (P =0.073)). High-dose folate had no significant effect on the intrauterine rate of growth in head circumference, and head circumference and brain weight at birth in our trial sample. However, the brain-body ratio of infants of mothers who received high-dose treatment was 0.33 percentage-point lower than that for infants of mothers who received the standard dose of folate (P =0.044). Higher strength folic acid supplementation in pregnant women who smoke might be a cost-effective and safe option to improve birth outcomes and reduce low birth weight and SGA associated infant morbidity and mortality. Future studies with larger sample sizes and diverse populations are indicated to confirm or refute the results of this study. Randomized controlled trials starting during the preconception period and with follow-up until delivery are warranted, to identify the most folate-sensitive period of fetal growth and determine the optimal dose of folic acid supplement. Further research investigating several pathways through which the effects of prenatal smoking on adverse birth outcomes can be mitigated is needed.

Objetivo: Avaliar se o efeito positivo de uma intervenção pró-aleitamento materno, direcionada a mães adolescentes e avós maternas, nas prevalências de amamentação no primeiro ano de vida mantinha-se aos dois anos de idade. Método: Este é a continuação de um ensaio clínico randomizado envolvendo 323 mães adolescentes, seus recém-nascidos e as avós maternas, quando em coabitação. A intervenção consistiu de seis sessões de aconselhamento em aleitamento materno, a primeira na maternidade e as demais no domicílio, aos 7, 15, 30, 60 e 120 dias. Nessas sessões eram abordados diversos assuntos relacionados ao aleitamento materno e, na última sessão, eram fornecidas orientações quanto à introdução da alimentação complementar saudável a partir dos seis meses. Os dados sobre a alimentação da criança foram obtidos mensalmente nos primeiros seis meses, a cada dois meses dos 6 aos 12 meses e quando as crianças tinham entre 4 e 7 anos. Para análise dos dados, utilizou-se modelo multivariável de regressão de Poisson com variância robusta, tendo como desfecho aleitamento materno aos dois anos de idade. Resultados: A manutenção do aleitamento materno por dois anos ou mais ocorreu em 32,2% da amostra. Quando comparados os grupos intervenção e controle, a prevalência de AM aos dois anos foi semelhante (29,9% vs. 34,3%, respectivamente; p=0,605). A análise multivariável não mostrou associação entre exposição à intervenção e manutenção da amamentação por dois anos ou mais nos diferentes modelos testados. Conclusões: O impacto positivo da intervenção testada nas prevalências de aleitamento materno no primeiro ano de vida não se manteve aos dois anos de idade. / Objective: To assess whether the positive effects of a pro-breastfeeding intervention directed at adolescent mothers and maternal grandmothers on the prevalence of breastfeeding observed in the first year of life were maintained at 2 years of age. Method: This study is the continuation of a randomized clinical trial conducted between 2006 and 2008 involving 323 adolescent mothers, their newborns and maternal grandmothers when cohabitating. The intervention consisted of six breastfeeding counseling sessions, the first one held at the maternity ward and the others at the participants’ homes at 7, 15, 30, 60, and 120 days postpartum. The sessions covered different topics related to breastfeeding; in the last session, guidance was provided on the introduction of healthy complementary feeding as of 6 months of age. Data on infant feeding were obtained monthly during the first 6 months, every 2 months between 6 and 12 months of age, and when the children were 4 to 7 years old. Data were analyzed using multivariable Poisson regression model with robust variance, with breastfeeding at 2 years of age as the outcome. Results: Maintenance of breastfeeding for 2 years or more was present in 32.2% of the sample. When the intervention and control groups were compared, the prevalence of breastfeeding at 2 years was similar (29.9 vs. 34.3%, respectively; p=0.605). Multivariable analysis did not reveal an association between exposure to the intervention and maintenance of breastfeeding for 2 years or more in the different models tested. Conclusions: The positive impact of the intervention on the prevalence of breastfeeding observed in the first year of life was not maintained at 2 years of age.

Objetivo: Avaliar o impacto do tratamento periodontal na concentração sérica de proteína C-reativa (PCR), perfil lipídico e hemoglobina glicada em pacientes cardiopatas participantes de um ensaio clínico randomizado com análise de 12 meses de acompanhamento. Métodos: Trata-se de um ensaio clínico randomizado em hospital terciário com pacientes com doença arterial coronariana (DAC) estável e periodontite crônica grave. Foram realizados exames periodontais (seis sítios por dente em toda a boca) para registro de profundidade de sondagem (PS) e perda de inserção (PI), além de índice de placa visível (IPV) e índice de sangramento gengival (ISG). O grupo teste recebeu tratamento periodontal intensivo, sendo inicialmente realizada uma sessão de raspagem, alisamento e polimento supragengival (RAP) com orientação personalizada de higiene bucal. Em seguida, foram realizadas até quatro sessões de raspagem e alisamento radicular subgengival (RASUB) por quadrante, sob anestesia local. O grupo controle recebeu uma única sessão de RAP e orientação de higiene bucal. Foram coletadas amostras para mensuração dos níveis sistêmicos de PCR de alta sensibilidade, perfil lipídico e hemoglobina glicada. Resultados: 60 pacientes foram analisados após 12 meses, 28 no grupo teste e 32 no grupo controle, com idade média de 59 e 61 anos, respectivamente. Não foram observadas diferenças significativas ao longo do tempo, e entre os grupos nos dois tempos experimentais em relação a PCR. Assim como não foram encontradas diferenças significativas entre perfil lipídico e hemoglobina glicada. Conclusão: O tratamento periodontal não adicionou benefício sobre os níveis de PCR, hemoglobina glicada e perfil lipídico em indivíduos cardíacos crônicos tratados em uma unidade terciária. No entanto, foi observada uma tendência de benefício em pacientes cardíacos com níveis basais controlados de PCR. / Objective: To evaluate the impact of periodontal therapy on serum concentration of CRP, lipid profile and glycated hemoglobin in patients with heart disease participating in a randomized clinical trial with 12 months of follow-up. Methods: A randomized clinical trial in a tertiary hospital with patients with stable coronary artery disease (CAD) and severe chronic periodontitis. Whole mouth periodontal examination (six sites per tooth) was performed and comprised probing depth (PD) and attachment loss, in addition to visible plaque (VPI) and gingival bleeding index (GBI) The test group received intensive periodontal treatment. Initially, supragingival scaling with oral hygiene instruction were performed. In sequence, up to four sessions of subgingival scaling root planing per quadrant, under local anesthesia were performed. The control group had supragingival scaling and oral hygiene instruction. Blood samples were collected to assess the serum levels of high sensitivity CRP, lipid profile and glycated hemoglobin. Results: A total of 60 patients were analyzed after twelve moths, 28 (test group) and 32 (control group), with a mean age of 59 and 61 years. No statistically significant differences were observed along the study between groups in CRP. Also, no statistically significant diferences were detected in glycated hemoblobin and lipid profile. Conclusion: Periodontal treatment did not add benefit on CRP and glycated hemoglobina levels as well as in lipid profile in chronic cardiac individuals treated in a tertiary unit. However, a positive trend was observed in cardiac patients with controlled RCP basal levels.